<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006811.pub3" GROUP_ID="INJ" ID="858506092816575205" MERGED_FROM="" MODIFIED="2014-10-20 14:57:17 +0100" MODIFIED_BY="Emma Sydenham" REVIEW_NO="INJ0093" REVMAN_SUB_VERSION="5.2.8 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-10-20 11:58:29 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-02 17:51:02 +0100" MODIFIED_BY="Emma M Sydenham">Modest cooling therapies (35ºC to 37.5ºC) for traumatic brain injury</TITLE>
<CONTACT>
<PERSON ID="B157805582E26AA20078D4E6193D679A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Manoj</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Saxena</LAST_NAME>
<SUFFIX/>
<POSITION>Staff Specialist in Intensive Care</POSITION>
<EMAIL_1>m.saxena@unsw.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Intensive Care Unit</DEPARTMENT>
<ORGANISATION>St George Hospital</ORGANISATION>
<ADDRESS_1>Gray St</ADDRESS_1>
<ADDRESS_2>Kogarah</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>2217</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+ 61 2 9350 3269</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-10-20 11:57:43 +0100" MODIFIED_BY="Emma Sydenham">
<PERSON ID="B157805582E26AA20078D4E6193D679A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Manoj</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Saxena</LAST_NAME>
<SUFFIX/>
<POSITION>Staff Specialist in Intensive Care</POSITION>
<EMAIL_1>m.saxena@unsw.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Intensive Care Unit</DEPARTMENT>
<ORGANISATION>St George Hospital</ORGANISATION>
<ADDRESS_1>Gray St</ADDRESS_1>
<ADDRESS_2>Kogarah</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>2217</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+ 61 2 9350 3269</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="327DB1D882E26AA20114382D89407D1B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS>JD</MIDDLE_INITIALS>
<LAST_NAME>Andrews</LAST_NAME>
<SUFFIX>MD,MBChB,FRCA</SUFFIX>
<POSITION>Reader in Anaesthesia</POSITION>
<EMAIL_1>P.Andrews@ed.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Intensive Care &amp; Pain Medicine, University of Edinburgh</DEPARTMENT>
<ORGANISATION>Lead Clinician, Critical Care Services, Western General Hospital, LUHD</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Edinburgh</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="AB1FCF6182E26AA200F0756D3DCF7C99" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Andrew</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cheng</LAST_NAME>
<SUFFIX/>
<POSITION>Specialist Registrar in Anaesthesia &amp; Intensive Care</POSITION>
<EMAIL_1>athcheng@mac.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Intensive Care Unit</DEPARTMENT>
<ORGANISATION>St George Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9563 9500</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1010A33682E26AA201A4D5C6C5AE9FFA" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Kiran</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Deol</LAST_NAME>
<SUFFIX/>
<POSITION>Intensive care registrar</POSITION>
<EMAIL_1>kirand@gmp.usyd.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Intensive Care Unit</DEPARTMENT>
<ORGANISATION>St George Hospital</ORGANISATION>
<ADDRESS_1>Gray St</ADDRESS_1>
<ADDRESS_2>Kogarah</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>2217</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>(+61) 402 956 317</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="51408578547363875632110603164007" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Naomi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hammond</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>nhammond@georgeinstitute.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+61 (0) 404 457 790</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Critical Care and Trauma Division</DEPARTMENT>
<ORGANISATION>The George Institute for Global Health</ORGANISATION>
<ADDRESS_1>Level 7, 341 George St</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2000</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-08-18 10:38:24 +0100" MODIFIED_BY="Emma Sydenham">
<UP_TO_DATE>
<DATE DAY="23" MONTH="9" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="9" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-10-20 11:58:29 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-10-20 11:58:29 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>Minor edits made to the text to improve clarity.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-10-20 11:58:04 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-10-20 11:58:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="8" YEAR="2014"/>
<DESCRIPTION>
<P>All declaration of interest statements from the authors are now included in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-08-21 14:22:34 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>The search for studies has been updated to 23 September 2013.</P>
<P>One ongoing study was identified (<LINK REF="STD-NCT01231139" TYPE="STUDY">NCT01231139</LINK>), and its results will be included into the review by the end of 2015.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-08-21 14:22:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>The authors of the review have changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR" MODIFIED="2008-05-08 11:42:06 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="5" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>Protocol first published.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-04-13 01:29:28 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-04-13 01:29:28 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-04-13 01:29:28 +0100" MODIFIED_BY="[Empty name]">
<NAME>Professor Peter Andrews</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Supported by the University of Edinburgh</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-10-20 14:49:52 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-10-20 11:58:53 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-08-11 17:11:34 +0100" MODIFIED_BY="[Empty name]">Interventions that aim to reduce body temperature to between 35 ºC and 37.5 ºC in patients who have had a traumatic brain injury within the last week</TITLE>
<SUMMARY_BODY MODIFIED="2014-10-20 11:58:53 +0100" MODIFIED_BY="[Empty name]">
<P>Traumatic brain injury (an injury to the brain that occurs as a result of a direct impact, such as may occur after a road traffic accident or a fall) is a major cause of death and long-term disability worldwide. There is some evidence from animal experiments that reducing body temperature after brain injury may improve outcomes. There is also some evidence in humans to suggest that people with a normal body temperature after traumatic brain injury may have a better outcome than those with a higher temperature. </P>
<P>The authors of this Cochrane review looked for evidence that reducing body temperature to between 35 ºC and 37.5 ºC would benefit patients in the week after traumatic brain injury. We looked for studies on the use of physical or drug-induced cooling on patients with a traumatic brain injury. Physical cooling techniques include cooling blankets, use of ice, fans or other devices. Chemical cooling techniques include drugs used to reduce fever, like paracetamol (acetaminophen).</P>
<P>We did not find any randomised controlled trials or controlled clinical trials that we could include in this review. Such studies represent the best form of evidence to determine whether a particular therapy works, because they limit the errors that may affect the interpretation of a study. Given the lack of eligible studies, the only finding we can present is that there is no satisfactory research carried out in relation to the specific question of the risks and benefits of cooling to between 35-37.5°C for patients with TBI. There is another Cochrane review (Hypothermia for traumatic head injury) about cooling below 35°C which includes a number of studies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-08-08 17:19:44 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-10-25 03:47:06 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Animal models of traumatic brain injury suggest that induced normothermia (36.5 or 37 ºC), compared to induced hyperthermia (39 ºC), improves histopathological and neurobehavioural outcomes. Observational clinical studies of patients with TBI suggest an association between raised body temperature and unfavourable outcome, although this relationship is inconsistent.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>To assess the effects of modest cooling therapies (defined as any drug or physical therapy aimed at maintaining body temperature between 35 ºC and 37.5 ºC) when applied to patients in the first week after traumatic brain injury.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-08-08 17:19:44 +0100" MODIFIED_BY="[Empty name]">
<P>The most recent search was run on 23<SUP>rd</SUP> September 2013. We searched the Cochrane Injuries Group's Specialised Register, The Cochrane Library (CENTRAL), MEDLINE (OvidSP), Embase (OvidSP), ISI WOS: SCI-EXPANDED (1970) &amp; CPCI-S (1990), PubMed and trials registries together with reference checking.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-07-31 14:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>All completed randomised, controlled and placebo-controlled trials published or unpublished, where modest cooling therapies were applied in the first week after traumatic brain injury.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-07-31 14:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently applied the selection criteria to relevant trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-31 14:23:09 +0100" MODIFIED_BY="[Empty name]">
<P>We were unable to find any randomised controlled trials of modest cooling therapies after traumatic brain injury.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-12-08 22:42:43 +0000" MODIFIED_BY="Emma M Sydenham">
<P>In order to further explore the preliminary findings provided by animal models and observational clinical studies that suggests there may be a beneficial effect of modest cooling for TBI, randomised trials designed to explore the effect of these interventions on patient-centred outcomes are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-10-20 14:49:52 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-10-20 14:46:55 +0100" MODIFIED_BY="[Empty name]">
<P>Traumatic brain injury (TBI) is a major cause of death and disability amongst a predominantly young population, with an estimated 10 million people experiencing severe TBI worldwide every year (<LINK REF="REF-Alexander-1992" TYPE="REFERENCE">Alexander 1992</LINK>). The World Health Organization Global Burdens of Disease Project identified road traffic crashes as the 4th leading cause of death in low and middle-income countries (<LINK REF="REF-Mathers-2001" TYPE="REFERENCE">Mathers 2001</LINK>) and road traffic injuries are consistently in the top 3 leading causes of death worldwide in the age group 5 to 44 years. TBI is an important issue that affects many people in developed and developing countries. There is, however, an important lack of coherent evidence about effective therapies for the acute care of these patients (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>).</P>
<P>Some data from animal studies (<LINK REF="REF-Dietrich-1996" TYPE="REFERENCE">Dietrich 1996</LINK>; <LINK REF="REF-Chatzipanteli-2007" TYPE="REFERENCE">Chatzipanteli 2007</LINK>) of TBI suggest that reducing body temperature by the intervention of induced normothermia (36.5 or 37 ºC), compared to artificially increasing body temperature by inducing hyperthermia (39 ºC), improves biochemical and histopathological outcomes. Observational data from clinical cohort studies also suggest that patients with an elevated body temperature (hyperthermia) may have a worse outcome than patients who have a normal body temperature (<LINK REF="REF-Geffroy-2004" TYPE="REFERENCE">Geffroy 2004</LINK>; <LINK REF="REF-Jiang-2002" TYPE="REFERENCE">Jiang 2002</LINK>; <LINK REF="REF-Li-2012" TYPE="REFERENCE">Li 2012</LINK>), but this relationship is inconsistent (<LINK REF="REF-Jones-1994" TYPE="REFERENCE">Jones 1994</LINK>; <LINK REF="REF-Stocchetti-N" TYPE="REFERENCE">Stocchetti N</LINK>; <LINK REF="REF-Andrews-2006" TYPE="REFERENCE">Andrews 2006</LINK>).</P>
<P>The clinical utility of reducing body temperature by cooling has yet to be conclusively demonstrated in terms of reduced mortality or improved functional survival in the clinical setting of TBI. There are now some data to support the use of induced hypothermia after perinatal birth asphyxia (body temperature reduction to 35 ºC) in neonates (<LINK REF="REF-Gluckman-2005" TYPE="REFERENCE">Gluckman 2005</LINK>). Pathophysiologically, TBI differs from neonatal birth asphyxia in that the primary insult is direct neuronal trauma and this is also frequently complicated by associated secondary insults. These include disorders of airway, breathing and circulation associated with the primary trauma that may result in secondary episodes of hypoxia, hypercarbia and low cardiac output (most commonly due to haemorrhage and hypovolaemia). The treatment effects of temperature reduction after neonatal birth asphyxia has not been replicated in patients with TBI and an existing Cochrane review (<LINK REF="REF-Sydenham-2009" TYPE="REFERENCE">Sydenham 2009</LINK>) has concluded that there is no evidence that induced hypothermia (defined as interventions that reduce core body temperature to 35 ºC or less) is beneficial in the treatment of traumatic head injury. In addition, this review suggested that there is an increase in pulmonary infections with the intervention of hypothermia compared to controls.</P>
<P>Arguably, induced hypothermia remains a complex, unproven intervention that could only be applied to a small proportion of the more severely injured patients who suffer a TBI, where advanced pre-hospital trauma care, intensive care facilities and skilled staff are readily available. On the other hand, we have argued that interventions that target a more modest temperature reduction may, if efficacy is demonstrated, be applicable to a much larger proportion of the global pool of patients who suffer a TBI (<LINK REF="REF-Andrews-2006" TYPE="REFERENCE">Andrews 2006</LINK>). Examples of interventions that may achieve a more modest temperature reduction than induced hypothermia include drug therapy (for example, paracetamol, acetaminophen, non-steroidal anti-inflammatory drugs, etc (<LINK REF="STD-Price-2003" TYPE="STUDY">Price 2003</LINK>)) and physical therapies (for example, bedside fans, tepid sponging, ice packs, cooling blankets, etc (<LINK REF="STD-Harris-2007" TYPE="STUDY">Harris 2007</LINK>)). We define modest cooling therapies as any intervention(s) that is (are) carried out with the intention of reducing body temperature to no less than 35 ºC. This includes interventions that are administered with the intention of lowering body temperature to below normal (less than 36 ºC but above 35 ºC), and those interventions that are given to maintain temperature within the range of greater than 36 ºC but less than 37.5 ºC (normothermia).</P>
<IMPORTANCE MODIFIED="2014-10-20 14:46:55 +0100" MODIFIED_BY="[Empty name]">
<P>The Brain Trauma Foundation (<LINK REF="REF-BTF-2007" TYPE="REFERENCE">BTF 2007</LINK>) does not make recommendations regarding modest cooling therapies after TBI, reflecting the lack of evidence for this intervention. At present, we believe that modest cooling therapies, as outlined above, are used in ad hoc fashion after TBI. We endeavoured to search for randomised controlled clinical trials that explore the effects of modest cooling therapies on outcomes following TBI. This systematic review aims to assess the relationship between imposed modest changes in body temperature and outcome after TBI, and determine whether there is any clear evidence that a modest temperature reduction of any kind is beneficial, has no effect, or causes harm.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-07-31 15:36:52 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of modest cooling therapies (with antipyretic drugs or physical cooling devices) when administered to patients (adult and children) admitted to hospital after TBI.</P>
<P>We defined modest cooling therapies as any interventions carried out with the intention of reducing body temperature to no less than 35 ºC (this excludes studies identified in the Cochrane review titled 'Hypothermia for traumatic head injury' (<LINK REF="REF-Sydenham-2009" TYPE="REFERENCE">Sydenham 2009</LINK>) as this review assesses the effect of interventions that reduce temperature to below 35 ºC).</P>
<P>We wished to test the following hypotheses:</P>
<OL>
<LI>Modest cooling therapies reduce the risk of a poor outcome after traumatic brain injury (a poor outcome is defined as the composite end-point of death or severe disability).</LI>
<LI>Modest cooling therapies increase the risk of intracranial and extracranial bleeding.</LI>
<LI>Modest cooling therapies increase the risk of pneumonia or other serious infections.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2014-08-18 10:35:52 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-08-06 12:27:06 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-05-07 13:18:26 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Randomised, controlled trials of interventions administered to patients within the first week after TBI, that aim to reduce body temperature to no less than 35 ºC.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All patients admitted to hospital following TBI (all severities).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-06-20 02:00:48 +0100" MODIFIED_BY="Naomi E Hammond">
<P>Any physical or drug therapy that reduces temperature to no less than 35 ºC.</P>
<P>Examples of physical therapy include bedside fans, sponging, fluid or air-filled devices applied to body surfaces (for example, blankets, neck-collars, helmets or hoods), ice-water lavage or intravenous fluid administration and intravenous cooling catheters.</P>
<P>Examples of drug therapies include acetaminophen, paracetamol, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors given by any route.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-08-06 12:27:06 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-08-06 11:56:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Poor outcome at the end of follow up. This is defined as death or dependency as measured by the Glasgow Outcome Score (GOS), or an equivalent method in which it is clear how many people are dependent and how many are independent at the end of the follow-up period. This is the most important outcome as the aim of treatment should not only be to prevent death, but also to improve the quality of the patient's survival.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-08-06 12:27:06 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death from all causes during the follow-up period.</LI>
<LI>Further serious intracranial haemorrhage: this is defined as the need for operative intervention (for example, evacuation of subdural or extradural haematoma) occurring during the period of intervention.</LI>
<LI>Extracranial haemorrhage: defined as the need for transfusion of greater than two units of packed cells within a 24-hour period occurring during the period of intervention.</LI>
<LI>Abnormal Intracranial Pressure: This is defined as an intracranial pressure of more than 20mmHg as measured by an intracranial pressure monitor.</LI>
<LI>Pneumonia or other serious infections.</LI>
</UL>
<P>Information size requirement for the primary outcome:<BR/>With a conventional dichotomous analysis of the GOS that compares the proportions of patients with an unfavourable outcome in the two groups (normothermia vs. control), a minimum of 716 people need to be randomised in order to have 90% power at the 5% significance level (2-sided) to detect an absolute reduction of 12% (60% reducing to 48%) of an unfavourable outcome. 
</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-08-08 17:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>In order to reduce publication and retrieval bias we did not restrict our search by language, date or publication status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-08-08 17:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Injuries Group's Trials Search Co-ordinator searched the following:</P>
<OL>
<LI>Cochrane Injuries Group's Specialised Register (23rd September 2013);</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library) Issue 9 of 12, 2013;</LI>
<LI>MEDLINE (OvidSP) (1950 to Sept 18th, 2013);</LI>
<LI>Embase (OvidSP) (1980 to week 37, 2013);</LI>
<LI>ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970 to September 2013);</LI>
<LI>ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S) (1990 to September 2013);</LI>
<LI>Pubmed (23rd September 2013);</LI>
<LI>National Research Register (issue 3, 2007);</LI>
<LI>ZETOC (<A HREF="http://zetoc.mimas.ac.uk/">http://zetoc.mimas.ac.uk/</A>) (April 2008).</LI>
</OL>
<P>The National Research Register has now been archived and ZETOC has not retrieved any additional studies therefore these sources were not searched for this update. Their search strategies are listed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>On 9 December 2013 the authors searched:</P>
<OL>
<LI>Clinicaltrials.gov <A HREF="http://(www.clinicaltrials.gov)">(www.clinicaltrials.gov)</A>;</LI>
<LI>Current Controlled Trials M<I>eta</I>Register (<A HREF="http://www.controlled-trials.com/mrct/">http://www.controlled-trials.com/mrct/</A>).</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-08-06 11:40:34 +0100" MODIFIED_BY="[Empty name]">
<P>We checked reference lists of selected studies and relevant reviews to find additional studies and contacted the authors of relevant studies to assist in the identification of unpublished studies, internal reports and conference proceedings. On 9 December 2013 we contacted the investigators, pharmaceutical companies and manufacturers of cooling equipment that are pertinent to this field (listed in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-08-18 10:35:52 +0100" MODIFIED_BY="[Empty name]">
<P>The review was conducted according to the published protocol (<LINK REF="REF-Saxena-2007" TYPE="REFERENCE">Saxena 2007</LINK>).</P>
<STUDY_SELECTION MODIFIED="2014-07-31 14:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (MS and NH) independently screened the titles and abstracts and discarded studies that did not meet the review criteria or were not applicable; however, we initially retained studies and reviews that might include relevant data or information on ongoing trials. The authors then independently reviewed the retrieved studies, examining the abstracts and the full text to ascertain which studies satisfied the necessary inclusion criteria. We also screened references from the studies retrieved in full-text.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-07-31 14:39:22 +0100" MODIFIED_BY="[Empty name]">
<P>The same authors independently carried out data extraction using standard data extraction forms. We translated non-English language studies before assessment. We requested any further information required from the original author by written correspondence and considered the relevant information obtained in this manner as part of the review. We resolved disagreements in consultation with the third author (PA).</P>
<P>In the future the following information will be extracted from each assessed study: the title of the trial; the intervention being tested (dosage and route for drug therapy; physical cooling method for equipment); lowest body temperature attained; duration of intervention; the time interval between the onset of the initial injury and the commencement of cooling therapy; and, any neurological deterioration developing after the commencement of cooling therapy. We will also record the total number of patients randomised to intervention and placebo-controlled groups. We will also collect data on age, gender, mechanism of injury, associated extracranial injuries and duration from injury to presentation at a hospital.</P>
<P>We will also record specific information regarding the number of patients in each group with the following outcomes: death and dependency, death alone, intracranial haemorrhage, extracranial haemorrhage, pneumonia, other serious infections, any other complications, and the number of patients excluded or lost to follow up.</P>
<P>For each study, we will also assess whether an intention-to-treat analysis was used according to the following criteria:</P>
<UL>
<LI>Yes - specifically reported by the authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>Yes - not stated, but confirmed on study assessment.</LI>
<LI>No - not reported and lack of intention-to-treat analysis confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study, or were not included because of protocol violation).</LI>
<LI>No - stated but not confirmed upon study assessment.</LI>
<LI>Not stated.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-07-31 14:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>In the future if studies are included in this review, two authors will independently assess the quality of studies meeting the inclusion criteria, without blinding to authorship or journal. Discrepancies will be resolved by discussion. We will follow the most recent version of the risk of bias criteria, as described in chapter 8 of the Cochrane Handbook (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We will assess the methods used to generate the randomisation sequence, concealment of the randomisation sequence (allocation concealment), blinding of investigators, participants, outcome assessors, and those involved in data analysis. We will consider there to be no blinding if the treatment group can be identified in &gt;20% of participants because of the side effects of treatment. We will also assess how complete the outcome data are, whether there is selective reporting of the outcome measures, and any other sources of bias. </P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-07-31 14:44:16 +0100" MODIFIED_BY="[Empty name]">
<P>We will calculate the risk ratio with 95% confidence intervals for dichotomous outcomes. </P>
<P>For continuous outcomes measured on the same scale, we will calculate the mean difference (MD) and 95% confidence intervals. If results for continuous outcomes are reported using different scales or different versions of the same scale, we will calculate the standardised mean difference (SMD) and 95% CI.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-12-08 23:36:31 +0000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis will be the individual patient.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-08-14 15:58:42 +0100" MODIFIED_BY="[Empty name]">
<P>Missing summary data will not be a reason to exclude a study from the review. If necessary, we will contact the authors of the original papers for more information on missing data. If an eligible study is identified but provides no useable data for analysis, the study will still be included in the review. Its methods will be described in the table of included studies, and an assessment of the risk of bias will be completed.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-07-31 14:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>We will consider clinical homogeneity among all included studies. For studies considered as clinically homogeneous, we will test the statistical heterogeneity using the Chi<SUP>2</SUP> test and I<SUP>2</SUP> statistic. We will assume statistical significance of the Chi<SUP>2</SUP> test if P &lt; 0.10. We will consider an I<SUP>2</SUP> value greater than 50% to be substantial.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-12-08 23:45:31 +0000" MODIFIED_BY="[Empty name]">
<P>If there are ten or more studies included in an analysis, funnel plots and linear regression tests will be used to assess for any potential reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-07-31 14:48:25 +0100" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes we will express the results as relative risk (RR) with 95% confidence intervals (CI). We will pool data using the random-effects model. Where continuous scales of measurement are used to assess the effects of treatment, we will use the mean difference (MD), or the standardised mean difference (SMD) if different scales have been used. We will analyse heterogeneity using a Chi-squared test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance, and with the I<SUP>2</SUP> test.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-08-18 10:35:52 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible, we will explore the following:</P>
<OL>
<LI>Adults (&gt;18 years old) versus children;</LI>
<LI>Achieved temperature reduction (35 ºC to 36 ºC versus placebo and 36 ºC to 37.5 ºC versus placebo);</LI>
<LI>Duration of temperature reduction.</LI>
</OL>
<P>We will use subgroup analysis to explore possible sources of heterogeneity. We will tabulate and assess adverse effects with descriptive techniques, as they are likely to be different for the various interventions being assessed. Where possible, we will calculate the risk difference with 95% CI for each adverse event, compared to no treatment.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-10-20 14:49:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-10-20 14:49:23 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-10-20 14:49:23 +0100" MODIFIED_BY="[Empty name]">
<P>The electronic database searches have retrieved a total of 1395 records to September 2013. Contact with investigators, pharmaceutical companies and manufacturers of cooling equipment did not yield any further information. The updated searches in 2013 identified one new ongoing study (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="STD-NCT01231139" TYPE="STUDY">NCT01231139</LINK>). This study completed recruitment in 2014, and the results will be included into this review by the end of 2015.</P>
<P>In the first version of this review, which was published in 2008, we retrieved 12 articles for further consideration. Following a complete assessment of the 12 studies, we excluded two as the intervention of selective brain cooling with a target brain temperature of 33 ºC to 35 ºC was felt by all three authors of this review to be outside the scope of our review (<LINK REF="STD-Qiu-2006a" TYPE="STUDY">Qiu 2006a</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>).</P>
<P>After assessment of the remaining 10 studies, none were found to meet all the inclusion criteria for this review. In nine of the studies, information was provided on physiological end-points only, without reference to patient-centred outcomes and only four studies were placebo-controlled. </P>
<P>There was one randomised, placebo-controlled study of patients after TBI that included a group of patients with a modest temperature intervention (<LINK REF="STD-Qiu-2006" TYPE="STUDY">Qiu 2006</LINK>) and reported information on patient-centred outcomes. This study included two treatment arms (selective brain cooling to 33 ºC to 35 ºC and mild systemic hypothermia to 34.5 ºC to 36 ºC) with one control group; however, the control group was also subject to temperature cooling strategies. Following contact with the authors, this study was excluded because of methodological issues, as outcome data was lacking in 40 out of the 96 patients initially randomised in the study.</P>
<P>There were no studies included in the first or second versions of this review.</P>
</SEARCH_RESULTS>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-31 14:50:20 +0100" MODIFIED_BY="[Empty name]">
<P>There are no studies included in this review.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-07-31 14:50:28 +0100" MODIFIED_BY="[Empty name]">
<P>There are no studies included in this review.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-07-31 14:53:02 +0100" MODIFIED_BY="[Empty name]">
<P>We were unable to identify any randomised, controlled trials of modest cooling after TBI meeting the inclusion criteria.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-10-20 14:49:52 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-07-31 14:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>There are no completed randomised controlled trials of modest cooling for people with TBI. Therefore, the routine application of therapy aimed at maintaining body temperature between 35 ºC and 37.5 ºC cannot be recommended at present.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-10-20 14:49:52 +0100" MODIFIED_BY="[Empty name]">
<P>Trials with cooling strategies aimed at reducing body temperature to between 35 ºC and 37.5 ºC in the first week after TBI are needed.</P>
<P>Ideally trials should be placebo-controlled as it is important to answer the question of whether intervening to alter the natural history of body temperature after TBI has an effect on death and disability.  As physical and drug therapies may have independent mechanisms of action a factorial design is possible. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-08-14 16:10:08 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank the Cochrane Injuries Group Editorial Base, the Cochrane Renal Group and the authors of the previous Cochrane reviews 'Therapeutic hypothermia for head injury' (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>) and 'Cooling therapy for acute stroke' (<LINK REF="REF-Den-Hertog-2009" TYPE="REFERENCE">Den Hertog 2009</LINK>). We are grateful to Dr Doris Lam for her help in translating literature from Chinese journals.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-08-21 14:20:14 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Manoj Saxena: I am engaged in an investigator-initiated research program to answer the question of whether normothermia reduces death and disability after acute neurological illnesses (PARITY Study).</P>
<P>Naomi Hammond: None known.</P>
<P>Kiran Deol: I am an Intensive Care Doctor involved in the treatment of patients with head injury. I am also involved in other academic research in the area of head injury.</P>
<P>Andrew Cheng: None known.</P>
<P>Professor Peter Andrews: I am chief investigator of an international clinical trial of titrated therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury (NIHR HTA Funded).<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-08-18 10:25:08 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Manoj Saxena: conception and design of the review; development of all stages of the review; drafting the review and revising the review according to comments; contact with pharmaceutical companies; final version to be published.</P>
<P>Naomi Hammond and Kiran Deol: assessing the trials for inclusion criteria and extracting data; drafting and revising the review.</P>
<P>Andrew Cheng: assessing the trials for inclusion and extracting data (original review), drafting and revising the review.</P>
<P>Professor Peter Andrews: conception of the review; assessing the trials for inclusion criteria; drafting and revising the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-08-14 16:17:42 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-08-14 16:17:42 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-04-10 07:25:42 +0100" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES MODIFIED="2014-08-14 16:17:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andrews-2005" MODIFIED="2008-05-02 17:49:05 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Andrews 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-02 17:49:05 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrews PJ, Harris B, Murray GD</AU>
<TI>Randomized controlled trial of effects of the airflow through the upper respiratory tract of intubated brain-injured patients on brain temperature and selective brain cooling</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>3</NO>
<PG>330-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cormio-2007" MODIFIED="2014-08-14 16:17:42 +0100" MODIFIED_BY="[Empty name]" NAME="Cormio 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-14 16:17:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cormio M, Citerio G</AU>
<TI>Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care</TI>
<SO>Neurocritical Care</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>2</NO>
<PG>82-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diringer-2004" MODIFIED="2008-04-21 15:33:49 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Diringer 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-04-21 15:33:49 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diringer MN for the Neurocritical Care Fever Reduction Trial Group</AU>
<TI>Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>2</NO>
<PG>559-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-2007" MODIFIED="2008-05-02 17:48:52 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Harris 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-05-02 17:48:52 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris BA, Andrews PJ, Murray GD</AU>
<TI>Enhanced upper respiratory tract airflow and head fanning reduce brain temperature in brain-injured, mechanically ventilated patients: a randomized, crossover, factorial trial</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2007</YR>
<VL>98</VL>
<NO>1</NO>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinz-2007" MODIFIED="2008-04-21 15:34:14 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Hinz 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-04-21 15:34:14 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hinz J, Rosmus M, Popov A, Moerer O, Frerichs I, Quintel M</AU>
<TI>Effectiveness of an intravascular cooling method compared with a conventional cooling technique in neurologic patients</TI>
<SO>Journal of Neurosurgical Anesthesiology</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>2</NO>
<PG>130-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoedemaekers-2007" MODIFIED="2008-04-21 15:34:25 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Hoedemaekers 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-04-21 15:34:25 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoedemaekers CW, Ezzahti M, Gerritsen A, van der Hoeven J</AU>
<TI>Comparison of cooling methods to induce and maintain normo- and hypothermia in intensive care unit patients: a prospective intervention study</TI>
<SO>Critical Care</SO>
<YR>2007</YR>
<VL>11</VL>
<PG>R91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayer-2001" MODIFIED="2008-04-21 15:34:41 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mayer 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-04-21 15:34:41 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayer SA, Commichau C, Scarmeas N, Presciutti M, Bates J, Copeland D</AU>
<TI>Clinical trial of an air-circulating cooling blanket for fever control in critically ill neurologic patients</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>3</NO>
<PG>292-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayer-2004" MODIFIED="2008-04-21 15:34:53 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mayer 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-04-21 15:34:53 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayer SA, Kowalski RG, Presciutti M, Osiapkovich ND, McGann E, Fitzsimmons BF et al</AU>
<TI>Clinical trial of a novel surface cooling system for fever control in neurocritical care patients</TI>
<SO>Critical Care Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<NO>12</NO>
<PG>2508-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-2003" MODIFIED="2008-04-21 15:35:04 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Price 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-04-21 15:35:04 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price T, McGloin S, Izzard J, Gilchrist M</AU>
<TI>Cooling strategies for patients with severe cerebral insult in ICU (Part 2)</TI>
<SO>Nursing in Critical Care</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>1</NO>
<PG>37-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Qiu-2006" MODIFIED="2008-05-02 17:48:37 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Qiu 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-02 17:48:37 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Contact with author via email shihai954@163.com (Qiu WS) yielde the following information. The placebo arm did have therapies that reduced body temperature to &amp;quot;normothermia&amp;quot; (details not given). There was no intention to treat analysis carried out. 40 of the 96 randomised patients did not have patient centred outcome data. The study was hence excluded from the review.&lt;/p&gt;" NOTES_MODIFIED="2008-05-02 17:48:37 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiu WS, Wang WM, Du HY, Liu W, Shen H, Shen L et al</AU>
<TI>Thrombocytopaenia after therapeutic hypothermia in severe traumatic brain injury</TI>
<SO>Chinese Journal of Traumatology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>4</NO>
<PG>238-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Qiu-2006a" MODIFIED="2008-04-21 15:35:24 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Qiu 2006a" YEAR="2006">
<REFERENCE MODIFIED="2008-04-21 15:35:24 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiu W, Shen H, Zhang Y, Wang W, Liu W, Jiang Q et al</AU>
<TI>Non invasive selective brain cooling by head and neck cooling is protective in severe traumatic brain injury</TI>
<SO>Journal of Clinical Neurosciences</SO>
<YR>2006</YR>
<VL>13</VL>
<PG>995-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2008-05-02 17:48:10 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Wang 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-02 17:48:10 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Olivero W, Lanzino G, Elkins W, Rose J, Honings D et al</AU>
<TI>Rapid and selective cerebral hypothermia achieved using a cooling helmet</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2004</YR>
<VL>100</VL>
<PG>272-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-08-06 11:10:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01231139" MODIFIED="2014-08-06 11:10:57 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01231139" YEAR="2010">
<IDENTIFIERS MODIFIED="2014-08-06 11:10:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-06 11:10:52 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01231139"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-08-14 16:16:56 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-08-14 16:16:56 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2014-08-14 16:12:18 +0100" MODIFIED_BY="[Empty name]" NAME="Alderson 2004" TYPE="COCHRANE_REVIEW">
<AU>Alderson P, Gadkary C, Signorini DF</AU>
<TI>Therapeutic hypothermia for head injury</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-08-14 16:12:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-14 16:12:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001048.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alexander-1992" NAME="Alexander 1992" TYPE="JOURNAL_ARTICLE">
<AU>Alexander E Jr</AU>
<TI>Global Spine and Head Injury Prevention Project (SHIP)</TI>
<SO>Surgical Neurology</SO>
<YR>1992</YR>
<VL>38</VL>
<PG>478-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andrews-2006" NAME="Andrews 2006" TYPE="OTHER">
<AU>Andrews PJD, Anderson EL, Saxena MK</AU>
<TI>Cooling therapies after neuronal injury: direct brain cooling and systemic hypothermia</TI>
<SO>Intensive Care Yearbook</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTF-2007" NAME="BTF 2007" TYPE="JOURNAL_ARTICLE">
<AU>Brain Trauma Foundation</AU>
<TI>Guidelines for the management of severe traumatic brain injury</TI>
<SO>Journal of Neurotrauma</SO>
<YR>2007</YR>
<VL>24</VL>
<PG>s1-117</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chatzipanteli-2007" MODIFIED="2014-08-14 16:16:44 +0100" MODIFIED_BY="[Empty name]" NAME="Chatzipanteli 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chatzipanteli K, Alonso OF, Kraydieh S, Dietrich WD</AU>
<TI>Importance of posttraumatic hypothermia and hyperthermia on the inflammatory response after fluid percussion brain injury: biochemical and immunocytochemical studies</TI>
<SO>Journal of Cerebral Blood Flow &amp; Metabolism</SO>
<YR>2000</YR>
<VL>20</VL>
<PG>531-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Den-Hertog-2009" MODIFIED="2014-08-14 16:10:08 +0100" MODIFIED_BY="[Empty name]" NAME="Den Hertog 2009" TYPE="COCHRANE_REVIEW">
<AU>Den Hertog HM, van der Worp HB, Tseng MC, Dippel DWJ</AU>
<TI>Cooling therapy for acute stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2014-08-14 16:09:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-08-14 16:09:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001247.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dietrich-1996" MODIFIED="2013-10-25 04:11:08 +0100" MODIFIED_BY="[Empty name]" NAME="Dietrich 1996" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich WD, Alonso O, Halley M, Busto R</AU>
<TI>Delayed posttraumatic brain hyperthermia worsens outcome after fluid percussion brain injury: a light and electron microscopic study in rats</TI>
<SO>Neurosurgery</SO>
<YR>1996</YR>
<VL>38</VL>
<PG>533-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geffroy-2004" MODIFIED="2014-08-14 16:16:56 +0100" MODIFIED_BY="[Empty name]" NAME="Geffroy 2004" TYPE="JOURNAL_ARTICLE">
<AU>Geffroy A, Bronchard R, Merckx P, et al</AU>
<TI>Severe traumatic head injury in adults: which patients are at risk of early hyperthermia?</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>785-90</PG>
<IDENTIFIERS MODIFIED="2014-08-14 16:16:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gluckman-2005" NAME="Gluckman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, David Edwards A, Ferriero M et al</AU>
<TI>Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<PG>663-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-07-31 14:31:46 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</TI>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jiang-2002" MODIFIED="2014-08-14 16:15:51 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jiang JY, Gao GY, Li WP, Yu MK, Zhu C</AU>
<TI>Early indicators of prognosis in 846 cases of severe traumatic brain injury</TI>
<SO>Journal of Neurotrauma</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>869-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1994" MODIFIED="2014-08-14 16:15:35 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 1994" TYPE="JOURNAL_ARTICLE">
<AU>Jones P, Andrews P, Midgley S</AU>
<TI>Measuring the burden of secondary insults in head-injured patients during intensive care</TI>
<SO>Journal of Neurosurgical Anesthesiology</SO>
<YR>1994</YR>
<VL>6</VL>
<PG>4-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2012" MODIFIED="2014-08-14 16:14:36 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2012" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Jiang JY</AU>
<TI>Chinese Head Trauma Databank: effect of hyperthermia on the outcome of acute head trauma patients</TI>
<SO>Journal of Neurotrauma</SO>
<YR>2012</YR>
<VL>29</VL>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mathers-2001" MODIFIED="2008-05-07 13:43:30 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mathers 2001" TYPE="BOOK">
<AU>Mathers CD, Lopez AD, Murray CJL</AU>
<TI>The burden of disease and mortality by condition: data, methods and results from 2001. (Chapter 3)</TI>
<SO>The burden of disease and risk factors</SO>
<YR>2006</YR>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stocchetti-N" MODIFIED="2013-10-25 06:10:35 +0100" MODIFIED_BY="[Empty name]" NAME="Stocchetti N" TYPE="JOURNAL_ARTICLE">
<AU>Stocchetti N, Rossi S, Zanier ER et al</AU>
<TI>Pyrexia in head-injured patients admitted to intensive care</TI>
<SO>Intensive Care Med</SO>
<YR>2002</YR>
<VL>28</VL>
<PG>1555-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sydenham-2009" MODIFIED="2013-12-09 01:37:31 +0000" MODIFIED_BY="[Empty name]" NAME="Sydenham 2009" TYPE="COCHRANE_REVIEW">
<AU>Sydenham E, Roberts R, Alderson O</AU>
<TI>Hypothermia for traumatic head injury</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-12-09 01:37:31 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-09 01:37:31 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001048.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-07-31 16:11:29 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Saxena-2007" MODIFIED="2014-07-31 16:11:27 +0100" MODIFIED_BY="[Empty name]" NAME="Saxena 2007" TYPE="COCHRANE_PROTOCOL">
<AU>Saxena M, Andrews PJD, Cheng A</AU>
<TI>Modest temperature reduction for traumatic brain injury</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-07-31 16:11:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-31 16:11:27 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006811"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-08-14 16:00:58 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-04-10 07:25:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-04-10 07:27:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andrews-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-10 07:27:28 +0100" MODIFIED_BY="[Empty name]">
<P>Mixed patient cohort (9/15 TBI)</P>
<P>Physiological end-point (brain temperature)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Cormio-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Mixed patient cohort (12/22 TBI)</P>
<P>Physiological end-point (body temperature)</P>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Diringer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Mixed patient cohort (82/296 TBI)</P>
<P>Physiological end-point (body temperature)</P>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-10 07:27:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-10 07:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>Mixed patient cohort (8/12 TBI)</P>
<P>Physiological end-point (brain temperature)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Hinz-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Mixed patient cohort (5/26 TBI)</P>
<P>Physiological end-point (body temperature)</P>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Hoedemaekers-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Physiological end-point (body temperature)</P>
<P>Mixed patient cohort (11/25 TBI)</P>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Mayer-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Mixed patient cohort (27/220 TBI)</P>
<P>Physiological end-point (body temperature)</P>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Mayer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Mixed patient cohort (2/47 TBI)</P>
<P>Physiological end-point (body temperature)</P>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-04-10 07:24:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Price-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-04-10 07:24:06 +0100" MODIFIED_BY="[Empty name]">
<P>Mixed patient cohort (TBI number not specified, total 67)</P>
<P>Physiological end-point (body temperature)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Qiu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>No intention-to-treat analysis was carried out. After reviewing the study we contacted the authors and they confirmed that they did not carry out an intention-to-treat analysis.</P>
<P>Loss to follow up: 40 out of the 96 patients randomised did not have death or disability outcome data reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Qiu-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Intervention: selective brain cooling to brain temperature of 33 ºC to 35 ºC</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Wang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-02 17:47:21 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Intervention: selective brain cooling to brain temperature of 33 ºC to 35 ºC</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>TBI = traumatic brain injury</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-08-14 16:00:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-08-14 16:00:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01231139">
<CHAR_STUDY_NAME MODIFIED="2014-08-06 11:11:30 +0100" MODIFIED_BY="[Empty name]">
<P>The Paracetamol AfteR Traumatic Brain InjurY Study (PARITY)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-08-06 11:11:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised Controlled Trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-06 11:12:32 +0100" MODIFIED_BY="[Empty name]">
<P>Age &gt; 18 and &lt; 65</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-06 11:14:20 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: Paracetamol dissolved in 0.9% Sodium Chloride. Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).</P>
<P>Control: 0.9% Sodium Chloride. 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-14 16:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Core body temperature: bladder temperature probe (Time Frame: 30 minutes after final dose of study drug has been administered)<BR/>
<BR/>Secondary outcome measures:<BR/>(1) Blood Pressure (systolic and mean arterial pressure) measured by intra-arterial pressure monitor (Time Frame: 6 hourly during study treatment)<BR/>(2) Liver function test (Time Frame: daily from first dose of study treatment to the 7th day)<BR/>(3) Serum Paracetamol levels (blood analysis) after a single dose of study drug and after final dose of study drug. (Time Frame: baseline, 30, 45, 90, 240 minutes after single dose. 240 minutes after final dose of study drug)<BR/>(4) Temperature (bladder and tympanic) (Time Frame: Hourly from first study drug treatment until 4 hours after final study drug treatment) (Time-weighted mean, area under the 3-day temperature curve, daily maximum and minimum temperature)<BR/>(5) The use of physical cooling interventions (Time Frame: hourly during the period of study intervention)<BR/>(6) Intracranial pressure (Time Frame: 6 hourly during the period of study intervention) (Mean daily intracranial pressure for day 1, 2 and 3.)<BR/>(7) Incidence of cerebral hypoperfusion (Time Frame: During study intervention period)<BR/>(8) Systolic blood pressure &lt; 90 mmHg or Mean arterial pressure &lt; 50 mmHg for &gt; 15 minutes Cerebral perfusion pressure &lt; 50 mmHg for &gt; 15 minutes</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-08-06 11:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>October 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-08-06 11:20:00 +0100" MODIFIED_BY="[Empty name]">
<P>Manoj Saxena m.saxena@unsw.edu.au</P>
<P>Parisa Glass pglass@george.org.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-08-06 11:20:37 +0100" MODIFIED_BY="[Empty name]">
<P>As of 1 August 2014, the study has completed and the results will be included in the review within one year.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-04-10 07:25:42 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-04-10 07:25:42 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-08-14 15:59:47 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-08-14 15:59:47 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjIAAAUICAYAAACxijocAACAAElEQVR42uy9D0Sd/////2ZmZmYi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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-08-08 17:21:01 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-08-08 17:21:01 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-09-12 15:06:15 +0100" MODIFIED_BY="Karen Blackhall">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-08-08 17:21:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Cochrane Injuries Group Specialised Register</B>
</P>
<P>((((hypotherm* or cryotherap*) OR (temperature and reduc*) OR (&#8220;ice-water lavage&#8221;) OR (cold or cool*)) and (blanket* or helmet* or hood* or fluid* or catheter* or "neck collar")) OR ((intravenous) and (cold or cool*) and (fluid* or catheter*))) AND (INREGISTER) [REFERENCE] [STANDARD]</P>
<P>
<B>Cochrane Central Register of Controlled Trials (CENTRAL</B>)</P>
<P>#1MeSH descriptor: [Hypothermia] explode all trees<BR/>#2MeSH descriptor: [Hypothermia, Induced] explode all trees<BR/>#3MeSH descriptor: [Cryotherapy] explode all trees<BR/>#4hypotherm* or cryotherap*:ti,ab,kw (Word variations have been searched)<BR/>#5(cool* or cold) near/3 (therap* or device* or equipment):ti,ab,kw (Word variations have been searched)<BR/>#6(temperature near/3 reduc*):ti,ab,kw (Word variations have been searched)<BR/>#7intravenous near/3 (cold or cool*):ti,ab,kw (Word variations have been searched)<BR/>#8fluid* or catheter*:ti,ab,kw (Word variations have been searched)<BR/>#9#7 and #8<BR/>#10(cool* or cold*) near/3 (blanket* or neck collar* or helmet* or hood*):ti,ab,kw (Word variations have been searched)<BR/>#11ice-water lavage:ti,ab,kw (Word variations have been searched)<BR/>#12(#1 or #2 or #3 or #4 or #5 or #6 or #9 or #10 or #11)<BR/>#13MeSH descriptor: [Analgesics, Non-Narcotic] explode all trees<BR/>#14analgesic* near/3 (non-narcotic* or non-opioid*):ti,ab,kw (Word variations have been searched)<BR/>#15MeSH descriptor: [Acetaminophen] explode all trees<BR/>#16antipyretic*:ti,ab,kw (Word variations have been searched)<BR/>#17Aspirin or Meclofenamate sodium or Niflumic acid or Tiaprofenic acid or Tolfenamic acid or Acemetacine or Naproxen or Diclofenac or Etodolac or Fentiazac or Etofenamato or Fenbufen or Fentiazac or Nimesulid or Flurbiprofen or Ibuprofen or Indomethacin or Sulindac or ketoprofen or Lonazolac or Piroxicam or Tenoxicam or Proglumetacina or acetaminophen or paracetamol or acetamidophenol or hydroxyacetanilide or apap or acamol or acephen or acetaco or acetaminophen or algotropyl or anacin-3 or datril or n-4-hydroxyphenyl acetanilide or n-acetyl-p-aminophenol or panadol or Tylenol or p-acetamidophenol:ti,ab,kw (Word variations have been searched)<BR/>#18MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees<BR/>#19(analgesic* or non-steroidal) near/3 (anti-inflammator*):ti,ab,kw (Word variations have been searched)<BR/>#20NSAID* or anti-rheumatic* or aspirin-like:ti,ab,kw (Word variations have been searched)<BR/>#21(#13 or #14 or #15 or #16 or #17 or #18 or #19 or #20)<BR/>#22MeSH descriptor: [Body Temperature] explode all trees<BR/>#23MeSH descriptor: [Body Temperature Regulation] explode all trees<BR/>#24body near/3 temperature:ti,ab,kw (Word variations have been searched)<BR/>#25body near/3 (cool* or cold*):ti,ab,kw (Word variations have been searched)<BR/>#26(#22 or #23 or #24 or #25)<BR/>#27(#21 and #26)<BR/>#28MeSH descriptor: [Craniocerebral Trauma] explode all trees<BR/>#29MeSH descriptor: [Cerebrovascular Trauma] explode all trees<BR/>#30MeSH descriptor: [Brain Edema] explode all trees<BR/>#31MeSH descriptor: [Glasgow Coma Scale] explode all trees<BR/>#32MeSH descriptor: [Glasgow Outcome Scale] explode all trees<BR/>#33MeSH descriptor: [Unconsciousness] explode all trees<BR/>#34glasgow near/3 scale*:ti,ab,kw (Word variations have been searched)<BR/>#35Unconscious* or coma* or concuss* or 'persistent vegetative state':ti,ab,kw (Word variations have been searched)<BR/>#36Rancho Los Amigos Scale:ti,ab,kw (Word variations have been searched)<BR/>#37(head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) near/3 (injur* or trauma* or damag* or wound* or fracture* or contusion*):ti,ab,kw (Word variations have been searched)<BR/>#38Diffuse axonal injur*:ti,ab,kw (Word variations have been searched)<BR/>#39(#37 or #38)<BR/>#40(#32 or #33 or #34 or #35 or #36)<BR/>#41(#39 and #40)<BR/>#42(#28 or #29 or #30 or #39 or #41)</P>
<P>
<B>MEDLINE (OvidSP)</B>
<BR/>1. exp CRANIOCEREBRAL TRAUMA/<BR/>2. exp Cerebrovascular Trauma/<BR/>3. exp BRAIN EDEMA/<BR/>4. exp GLASGOW COMA SCALE/<BR/>5. exp GLASGOW OUTCOME SCALE/<BR/>6. exp UNCONSCIOUSNESS/<BR/>7. (glasgow adj3 scale*).ab,ti.<BR/>8. (Unconscious* or coma* or concuss* or 'persistent vegetative state').ab,ti.<BR/>9. Rancho Los Amigos Scale.ab,ti.<BR/>10. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or trauma* or damag* or wound* or fracture* or contusion*)).ab,ti.<BR/>11. Diffuse axonal injur$.ab,ti.<BR/>12. 10 or 11<BR/>13. 4 or 5 or 6 or 7 or 8 or 9<BR/>14. 12 and 13<BR/>15. (therapy or surgery or rehabilitation or diet therapy or drug therapy or Prevention &amp; Control).fs.<BR/>16. 12 and 15<BR/>17. 1 or 2 or 3 or 14 or 16<BR/>18. exp Hypothermia/<BR/>19. exp Hypothermia, Induced/<BR/>20. exp Cryotherapy/<BR/>21. (hypotherm$ or cryotherap$).ab,ti.<BR/>22. ((cool* or cold) adj3 (therap* or device* or equipment)).ab,ti.<BR/>23. (temperature adj3 reduc*).ab,ti.<BR/>24. (intravenous adj3 (cold or cool*) adj3 (fluid* or catheter*)).ab,ti.<BR/>25. ((cool* or cold*) adj3 (blanket* or neck collar* or helmet* or hood*)).ab,ti.<BR/>26. ice-water lavage.ab,ti.<BR/>27. or/18-26<BR/>28. exp Analgesics, Non-Narcotic/<BR/>29. (analgesic* adj3 (non?narcotic* or non?opioid*)).ab,ti.<BR/>30. exp Acetaminophen/<BR/>31. antipyretic$.ab,ti.<BR/>32. (Aspirin or Meclofenamate sodium or Niflumic acid or Tiaprofenic acid or Tolfenamic acid or Acemetacine or Naproxen or Diclofenac or Etodolac or Fentiazac or Etofenamato or Fenbufen or Fentiazac or Nimesulid or Flurbiprofen or Ibuprofen or Indomethacin or Sulindac or ketoprofen or Lonazolac or Piroxicam or Tenoxicam or Proglumetacina or acetaminophen or paracetamol or acetamidophenol or hydroxyacetanilide or apap or acamol or acephen or acetaco or acetaminophen or algotropyl or anacin-3 or datril or n-4-hydroxyphenyl acetanilide or n-acetyl-p-aminophenol or panadol or Tylenol or p-acetamidophenol).ab,ti.<BR/>33. exp Anti-Inflammatory Agents, Non-Steroidal/<BR/>34. ((analgesic* or non?steroidal) adj3 anti?inflammator*).ab,ti.<BR/>35. (NSAID* or anti?rheumatic* or aspirin-like).ab,ti.<BR/>36. or/28-35<BR/>37. exp Body Temperature/<BR/>38. exp Body Temperature Regulation/<BR/>39. (body adj3 temperature).ab,ti.<BR/>40. (body adj3 (cool* or cold*)).ab,ti.<BR/>41. or/37-40<BR/>42. 36 and 41<BR/>43. 27 or 42<BR/>44. 17 and 43<BR/>45. randomi?ed.ab,ti.<BR/>46. randomized controlled trial.pt.<BR/>47. controlled clinical trial.pt.<BR/>48. placebo.ab.<BR/>49. clinical trials as topic.sh.<BR/>50. randomly.ab.<BR/>51. trial.ti.<BR/>52. or/45-51<BR/>53. (animals not (humans and animals)).sh.<BR/>54. 52 not 53<BR/>55. 44 and 54</P>
<P>
<BR/>
<B>Embase (OvidSP)</B>
<BR/>1. exp Brain Injury/<BR/>2. exp Brain Edema/<BR/>3. exp Glasgow Coma Scale/<BR/>4. exp Glasgow Outcome Scale/<BR/>5. exp Rancho Los Amigos Scale/<BR/>6. exp Unconsciousness/<BR/>7. ((brain or cerebral or intracranial) adj3 (oedema or edema or swell*)).ab,ti.<BR/>8. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or trauma* or damag* or wound* or fracture* or contusion*)).ab,ti.<BR/>9. (Glasgow adj3 (coma or outcome) adj3 (scale* or score*)).ab,ti.<BR/>10. Rancho Los Amigos Scale.ab,ti.<BR/>11. (Unconscious* or coma* or concuss* or 'persistent vegetative state').ab,ti.<BR/>12. Diffuse axonal injur*.ab,ti.<BR/>13. ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)).ab,ti.<BR/>14. or/1-13<BR/>15. exp INDUCED HYPOTHERMIA/<BR/>16. exp HYPOTHERMIA/<BR/>17. exp cryotherapy/<BR/>18. (hypotherm$ or cryotherap$).ab,ti.<BR/>19. ((cool$ or cold) adj3 (therap$ or device$ or equipment)).ab,ti.<BR/>20. (temperature adj3 reduc$).ab,ti.<BR/>21. (intravenous adj3 (cold or cool$) adj3 (fluid$ or catheter$)).ab,ti.<BR/>22. ((cool$ or cold$) adj3 (blanket$ or neck collar$ or helmet$ or hood$)).ab,ti.<BR/>23. ice-water lavage.ab,ti.<BR/>24. or/15-23<BR/>25. (analgesic$ adj3 (non?narcotic$ or non?opioid$)).ab,ti.<BR/>26. exp Paracetamol/<BR/>27. antipyretic$.ab,ti.<BR/>28. (Aspirin or Meclofenamate sodium or Niflumic acid or Tiaprofenic acid or Tolfenamic acid or Acemetacine or Naproxen or Diclofenac or Etodolac or Fentiazac or Etofenamato or Fenbufen or Fentiazac or Nimesulid or Flurbiprofen or Ibuprofen or Indomethacin or Sulindac or ketoprofen or Lonazolac or Piroxicam or Tenoxicam or Proglumetacina or acetaminophen or paracetamol or acetamidophenol or hydroxyacetanilide or apap or acamol or acephen or acetaco or acetaminophen or algotropyl or anacin-3 or datril or n-4-hydroxyphenyl acetanilide or n-acetyl-p-aminophenol or panadol or Tylenol or p-acetamidophenol).ab,ti.<BR/>29. exp Nonsteroid Antiinflammatory Agent/<BR/>30. exp Antipyretic Analgesic Agent/<BR/>31. ((analgesic$ or non?steroidal) adj3 anti?inflammator$).ab,ti.<BR/>32. (NSAID$ or anti?rheumatic$ or aspirin-like).ab,ti.<BR/>33. or/25-32<BR/>34. exp body temperature/<BR/>35. exp Thermoregulation/<BR/>36. (body adj3 temperature).ab,ti.<BR/>37. (body adj3 (cool$ or cold$)).ab,ti.<BR/>38. or/34-37<BR/>39. 33 and 38<BR/>40. 24 or 39<BR/>41. 14 and 40<BR/>42. exp Randomized Controlled Trial/<BR/>43. exp controlled clinical trial/<BR/>44. randomi?ed.ab,ti.<BR/>45. placebo.ab.<BR/>46. Clinical Trial/<BR/>47. randomly.ab.<BR/>48. trial.ti.<BR/>49. or/42-48<BR/>50. exp animal/ not (exp human/ and exp animal/)<BR/>51. 49 not 50<BR/>52. 41 and 51</P>
<P>
<B>ISI Web of Science (SCI-EXPANDED; CPCI-S) </B>
</P>
<P>#35 #34 AND #29<BR/>#34 #33 AND #32<BR/>#33 TS=((human*))<BR/>#32 #31 OR #30<BR/>#31 TS=((randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly allocated OR at random OR<BR/>randomized controlled trial)) OR TS=((controlled clinical trial OR controlled trial OR clinical trial OR placebo))<BR/>#30 TS=(((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*)))<BR/>#29 #28 AND (#19 or #9)<BR/>#28 #27 OR #25<BR/>#27 #26 AND #25<BR/>#26 #22 OR #21 OR #20<BR/>#25 #24 OR #23<BR/>#24 TS=("Diffuse axonal injur*")<BR/>#23 TS=((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) near/3 (injur*<BR/>or trauma* or damag* or wound* or fracture* or contusion*))<BR/>#22 TS=(Rancho Los Amigos Scale)<BR/>#21 TS=(Unconscious* or coma* or concuss* or 'persistent vegetative state')<BR/>#20 TS=(glasgow near/3 scale*)<BR/>#19 #18 AND #15<BR/>#18 #17 OR #16<BR/>#17 TS=(body near/3 (cool* or cold*))<BR/>#16 TS=(body near/3 temperature)<BR/>#15 #14 OR #13 OR #12 OR #11 OR #10<BR/>#14 TS=(NSAID* or anti-rheumatic* or aspirin-like)<BR/>#13 TS=((analgesic* or non-steroidal) near/3 (anti-inflammator*))<BR/>#12 TS=(Aspirin or Meclofenamate sodium or Niflumic acid or Tiaprofenic acid or Tolfenamic acid or Acemetacine or Naproxen or Diclofenac or<BR/>Etodolac or Fentiazac or Etofenamato or Fenbufen or Fentiazac or Nimesulid or Flurbiprofen or Ibuprofen or Indomethacin or Sulindac or ketoprofen<BR/>or Lonazolac or Piroxicam or Tenoxicam or Proglumetacina or acetaminophen or paracetamol or acetamidophenol or hydroxyacetanilide or apap or<BR/>acamol or acephen or acetaco or acetaminophen or algotropyl or anacin-3 or datril or n-4-hydroxyphenyl acetanilide or n-acetyl-p-aminophenol or<BR/>panadol or Tylenol or p-acetamidophenol)<BR/>#11 TS=(antipyretic*)<BR/>#10 TS=(analgesic* near/3 (non-narcotic* or non-opioid*))<BR/>#9 #8 OR #7 OR #6 OR #3 OR #2 OR #1<BR/>#8 TS=(ice-water lavage)<BR/>#7 TS=((cool* or cold*) near/3 (blanket* or "neck collar*" or helmet* or hood*))<BR/>#6 #5 AND #4<BR/>#5 TS=(fluid* or catheter*)<BR/>#4 TS=(intravenous near/3 (cold or cool*))<BR/>#3 TS=((temperature near/3 reduc*))<BR/>#2 TS=((cool* or cold) near/3 (therap* or device* or equipment))<BR/>#1 TS=(hypotherm* or cryotherap*)</P>
<P>
<B>PubMed</B>
</P>
<P>((((((((((intravenous[title/abstract] AND (cold[title/abstract] OR cool*[title/abstract]) AND (fluid*[title/abstract] OR catheter*[title/abstract]))) OR ice-water lavage[Title/Abstract]) OR ((temperature[Title/Abstract]) AND reduc*[Title/Abstract])) OR ((hypotherm*[Title/Abstract]) OR cryotherap*[Title/Abstract])) OR ((((((((blanket*[Title/Abstract]) OR helmet*[Title/Abstract]) OR hood*[Title/Abstract]) OR fluid*[Title/Abstract]) OR catheter*[Title/Abstract]) OR neck collar*[Title/Abstract])) AND ((cool*[Title/Abstract]) OR cold*[Title/Abstract])))) AND (((((((("Comparative Study"[Publication Type]) OR "Randomized Controlled Trial"[Publication Type]) OR "Controlled Clinical Trial"[Publication Type])) OR (((((((randomized[Title/Abstract]) OR randomised[Title/Abstract]) OR placebo[Title/Abstract]) OR randomly[Title/Abstract]) OR trial[Title/Abstract]) OR groups[Title/Abstract]) OR group[Title/Abstract]))) NOT (("Animals"[Mesh]) NOT ("Animals"[Mesh] AND "Humans"[Mesh]))))) AND ((((((((((((head[Title/Abstract]) OR crani*[Title/Abstract]) OR cerebr*[Title/Abstract]) OR capitis[Title/Abstract]) OR brain*[Title/Abstract]) OR forebrain*[Title/Abstract]) OR skull*[Title/Abstract]) OR hemispher*[Title/Abstract]) OR intracran*[Title/Abstract]) OR intercran*[Title/Abstract]) OR (((haematoma*[Title/Abstract] OR hematoma*[Title/Abstract] OR haemorrhag*[Title/Abstract] OR hemorrhag*[Title/Abstract] OR bleed*[Title/Abstract] OR pressur*[Title/Abstract])) AND (head[Title/Abstract] OR crani*[Title/Abstract] OR cerebr*[Title/Abstract] OR brain*[Title/Abstract] OR intra?cran*[Title/Abstract] OR inter?cran*[Title/Abstract] OR intracran*[Title/Abstract] OR intercran*[Title/Abstract])) OR (((glasgow outcome scale[Title/Abstract]) OR glasgow coma scale[Title/Abstract]) OR rancho los amigos scale[Title/Abstract]) OR ((diffuse axonal injury[Title/Abstract]) OR diffuse axonal injuries[Title/Abstract]) OR ((brain[Title/Abstract] OR cerebral[Title/Abstract] OR intracranial[Title/Abstract]) AND (oedema[Title/Abstract] OR edema[Title/Abstract] OR swell*[Title/Abstract])) OR ((unconscious*[Title/Abstract] OR coma*[Title/Abstract] OR concuss*[Title/Abstract]) AND (injur*[Title/Abstract] OR trauma*[Title/Abstract] OR damag*[Title/Abstract] OR wound*[Title/Abstract] OR fracture*[Title/Abstract] OR contusion*[Title/Abstract] OR haematoma*[Title/Abstract] OR hematoma*[Title/Abstract] OR haemorrhag*[Title/Abstract] OR hemorrhag*[Title/Abstract] OR pressur*[Title/Abstract])) OR (((Coma[Mesh])) AND (injur*[title/abstract] OR trauma*[title/abstract] OR damag*[title/abstract] OR wound*[title/abstract] OR fractur*[title/abstract] OR contusion*[title/abstract] OR haematoma*[title/abstract] OR hematoma*[title/abstract] OR haemorrhag*[title/abstract] OR hemorrhag*[title/abstract] OR pressur*[title/abstract] OR lesion*[title/abstract] OR destruction*[title/abstract] OR oedema*[title/abstract] OR edema*[title/abstract] OR contusion*[title/abstract] OR concus*[title/abstract])))))) AND publisher[sb]</P>
<P>
<BR/>
</P>
<P>
<B>Current Controlled Trials </B>(<A HREF="http://www.controlled-trials.com/mrct/">http://www.controlled-trials.com/mrct/</A>)<BR/>((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) and (injur* or trauma* or damag* or wound* or fracture* or contusion*)) and (hypothermia or cooling)</P>
<P>
<B>ClinicalTrials.gov (</B>
<A HREF="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</A>
<B>)</B>
<BR/>(head OR brain) AND (hypothermia OR cooling)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-09-27 14:26:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-09-27 11:06:38 +0100" MODIFIED_BY="[Empty name]">Searches for previous versions</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-27 14:26:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>National Research Register 2007, issue 3</B>
<BR/>#1 MeSH descriptor Hypothermia explode all trees<BR/>#2 MeSH descriptor Hypothermia, Induced explode all trees<BR/>#3 MeSH descriptor Cryotherapy explode all trees<BR/>#4 hypotherm* or cryotherap*<BR/>#5 (cool* or cold) near3 (therap* or device* or equipment)<BR/>#6 (temperature near3 reduc*)<BR/>#7 intravenous near3 (cold or cool*)<BR/>#8 fluid* or catheter*<BR/>#9 (#7 AND #8)<BR/>#10 (cool* or cold*) near3 (blanket* or neck collar* or helmet* or hood*)<BR/>#11 ice-water lavage<BR/>#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #9 OR #10 OR #11)<BR/>#13 MeSH descriptor Analgesics, Non-Narcotic explode all trees<BR/>#14 analgesic* near3 (non-narcotic* or non-opioid*)<BR/>#15 MeSH descriptor Acetaminophen explode all trees<BR/>#16 antipyretic*<BR/>#17 Aspirin or Meclofenamate sodium or Niflumic acid or Tiaprofenic acid or Tolfenamic acid or Acemetacine or Naproxen or Diclofenac or Etodolac or Fentiazac or Etofenamato or Fenbufen or Fentiazac or Nimesulid or Flurbiprofen or Ibuprofen or Indomethacin or Sulindac or ketoprofen or Lonazolac or Piroxicam or Tenoxicam or Proglumetacina or acetaminophen or paracetamol or acetamidophenol or hydroxyacetanilide or apap or acamol or acephen or acetaco or acetaminophen or algotropyl or anacin-3 or datril or n-4-hydroxyphenyl acetanilide or n-acetyl-p-aminophenol or panadol or Tylenol or p-acetamidophenol<BR/>#18 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees<BR/>#19 (analgesic* or non-steroidal) near3 (anti-inflammator*)<BR/>#20 NSAID* or anti-rheumatic* or aspirin-like<BR/>#21 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)<BR/>#22 MeSH descriptor Body Temperature explode all trees<BR/>#23 MeSH descriptor Body Temperature Regulation explode all trees<BR/>#24 body near3 temperature<BR/>#25 body near3 (cool* or cold*)<BR/>#26 (#22 OR #23 OR #24 OR #25)<BR/>#27 (#21 AND #26)<BR/>#28 MeSH descriptor Craniocerebral Trauma explode all trees<BR/>#29 MeSH descriptor Cerebrovascular Trauma explode all trees<BR/>#30 MeSH descriptor Brain Edema explode all trees<BR/>#31 MeSH descriptor Glasgow Coma Scale explode all trees<BR/>#32 MeSH descriptor Glasgow Outcome Scale explode all trees<BR/>#33 MeSH descriptor Unconsciousness explode all trees<BR/>#34 glasgow near3 scale*<BR/>#35 Unconscious* or coma* or concuss* or 'persistent vegetative state'<BR/>#36 Rancho Los Amigos Scale<BR/>#37 (head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) near3 (injur* or trauma* or damag* or wound* or fracture* or contusion*)<BR/>#38 Diffuse axonal injur*<BR/>#39 (#37 OR #38)<BR/>#40 (#32 OR #33 OR #34 OR #35 OR #36)<BR/>#41 (#39 AND #40)<BR/>#42 (#28 OR #29 OR #30 OR #39 OR #41)<BR/>#43 (#27 AND #42)</P>
<P>
<B>ZETOC (April 2008)</B>
<BR/>head injur* cool*<BR/>OR<BR/>brain injur* cool*<BR/>OR<BR/>head injur* mild hypotherm*<BR/>OR<BR/>brain injur* mild hypotherm*<BR/>OR<BR/>head injur* modest hypotherm*<BR/>OR<BR/>brain injur* modest hypotherm*</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-08-06 11:41:11 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-05-02 17:59:49 +0100" MODIFIED_BY="Emma M Sydenham">Organisations contacted</TITLE>
<APPENDIX_BODY MODIFIED="2014-08-06 11:41:11 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the following pharmaceutical companies on 9 December 2013:</P>
<P>Reckitt Benckiser (aspirin and ibuprofen)<BR/>Merck Sharpe Dome (indomethacin and sulindac)<BR/>Novartis (diclofenac)<BR/>Mylan (meclofenamate sodium)<BR/>Cayman (neflumic acid)<BR/>Sanofi-Aventis (ketoprofen and tiaprofenic acid)<BR/>Galen (tolfenimic acid)<BR/>Pharma 24 (acemetacine)<BR/>Roche (naproxen and tenoxicam)<BR/>Wyeth-Lederle (etodolac, fentiazac and fenbufen)<BR/>Helsinn healthcare (nimesulide)<BR/>Pfizer (flurbiprofen and piroxicam)<BR/>Rotta (proglumetacin)<BR/>Johnson and Johnson (acetaminophan)<BR/>Bristol-Myers-Squibb (Paracetmol)</P>
<P>We also contacted the following manufacturers of cooling equipment on 9 December 2013:<BR/>Coolgard Cool line catheter (Alsius CA)<BR/>Tyco healthcare (Warmtouch 5800)<BR/>Gaymar USA (MTA 4702)<BR/>Arizant (Polar Air&#8482; Model 600 Air Cooling System) Cincinnati, Ohio (subzero)<BR/>Medivance (arctic sun temperature management system)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;0&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;0&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in previous version&lt;/p&gt;&lt;p&gt;0&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;NEW studies included&lt;/p&gt;&lt;p&gt;0&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;26&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records screened&lt;/p&gt;&lt;p&gt;667&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records after duplicates removed&lt;/p&gt;&lt;p&gt;667&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records identified through database searching&lt;/p&gt;&lt;p&gt;873&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# of additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of records excluded&lt;/p&gt;&lt;p&gt;641&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;2 were scientific abstracts of retrieved studies&lt;/p&gt;&lt;p&gt;1 was a systematic review&lt;/p&gt;&lt;p&gt;1 was a letter&lt;/p&gt;&lt;p&gt;21 studies were RCTs evaluating systemic hypothermia versus usual care/normothermia&lt;/p&gt;&lt;p&gt;1 was an ongoing study&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>